Trial Profile
Safety and Immunogenicity Studies of Pandemic Influenza (H1N1) 2009 Vaccine in Bergen.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Nov 2016
Price :
$35
*
At a glance
- Drugs Influenza A virus vaccine-H1N1 (Primary)
- Indications Influenza A virus H1N1 subtype
- Focus Adverse reactions
- Acronyms H1N1VAC
- 24 Oct 2016 Results of a comparative analysis from NCT01003288 and NCT01866540 studies published in the Vaccine.
- 14 Jul 2016 Status changed from recruiting to completed.
- 23 May 2013 Planned end date changed from 1 Dec 2013 to 1 Dec 2016 as reported by ClinicalTrials.gov.